PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-31.05%
Cash & equivalents declining -31.05% while Biotechnology shows -8.65% growth. Howard Marks would investigate if this cash drain is temporary or signals deeper issues.
No Data
No Data available this quarter, please select a different quarter.
-31.05%
Cash + STI yoy growth ≥ 1.5x the Biotechnology median of -7.94%. Joel Greenblatt would see a liquidity advantage if effectively redeployed.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.05%
Exceeding 1.5x Biotechnology median of 0.00%. Jim Chanos might suspect questionable capitalization or one-time items inflating current assets.
-31.37%
Current assets growth ≥ 1.5x the Biotechnology median of -6.74%. Joel Greenblatt sees a potential liquidity edge if well allocated.
76.50%
PP&E growth below half of Biotechnology median of -0.21%. Jim Chanos would suspect potential underinvestment or strategic shift away from core assets.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
9.08%
Below half the Biotechnology median of -0.11%. Jim Chanos sees a sharp divergence from peers, possibly a sign of strategic retreat or capital shortage.
No Data
No Data available this quarter, please select a different quarter.
-30.47%
≥ 1.5x the Biotechnology median of -5.00%. Joel Greenblatt sees more aggressive asset expansion than peers, but must confirm returns are adequate.
-21.72%
Payables growth above 1.5x Biotechnology median of 0.00%. Jim Chanos might see a warning sign of stressed supplier payments.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-21.72%
Below half Biotechnology median of 4.86%. Joel Greenblatt sees more conservative short-term leverage than peers.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-21.72%
Below half Biotechnology median of 0.98%. Joel Greenblatt sees a much lower liability expansion vs. peers.
0.01%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos suspects heavier share issuance than peers.
-3.53%
0.5-0.75x Biotechnology median of -4.85%. Guy Spier is cautious about weaker retention vs. peers.
-5.52%
Above 1.5x Biotechnology median 0.00%. Jim Chanos suspects a red flag if these gains are highly volatile.
No Data
No Data available this quarter, please select a different quarter.
-33.13%
≥ 1.5x Biotechnology median of -6.63%. Joel Greenblatt sees stronger equity growth vs. peers.
-30.47%
≥ 1.5x Biotechnology median of -5.06%. Joel Greenblatt sees more aggressive expansions than peers.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
31.05%
Above 1.5x Biotechnology median 10.87%. Jim Chanos sees a big jump in net debt. Potential leverage red flag.